Venetoclax and Azacitidine in Chinese patients with untreated acute myeloid leukemia ineligible for intensive chemotherapy  

作　　者：Leiming Xia Wanlu Tian Yiming Zhao Lingling Jiang Wei Qian Lei Jiang Ling Ge Jianjun Li Fengbo Jin Mingzhen Yang 

机构地区：[1]Department of Hematology,the first affiliated hospital of Anhui Medical University,Hefei,Anhui,230022,China [2]Anhui Public Health Clinical Center,Hefei,Anhui,230031,China [3]Anhui Provincial Institute of Translational Medicine,Hefei,Anhui,230092,China

出　　处：《Signal Transduction and Targeted Therapy》2023年第6期2451-2454,共4页信号转导与靶向治疗（英文）

摘　　要：Dear Editor,Acute Myeloid Leukemia(AML)patients are often found ineligible for aggressive standard chemotherapy in clinic because of old age and poor conditions.Current evidences suggest that targeted combination therapy might help these patients achieve a higher response rate with acceptable adverse events(AEs).^(1)Venetoclax(VEN),a selective small-molecule BCL2 inhibitor,combined with hypomethylating agent(HMA),such as azacytidine(AZA).

关 键 词：PATIENTS CHEMOTHERAPY ACUTE 

分 类 号：R733.71[医药卫生—肿瘤]